Technical Articles

Once viewed as a downstream effector, TSLP is now an upstream driver target of type 2 inflammation. This article traces its narrative from epithelial alarmin to anti-TSLP therapy milestones and translational research.

TSLP is a 159-amino-acid epithelial cytokine. This article follows a three-step relay - epithelial alarmin release, dendritic cell priming and basophil activation - that converts epithelial injury signals into type 2 immune responses.

In the fields of immunology and disease treatment, thymic stromal lymphopoietin (TSLP) is emerging as a rising star. As a pleiotropic cytokine belonging to the short-chain four-α-helix bundle type I IL-2 family, TSLP not only plays a key role in allergic and autoimmune diseases but also demonstrates unique regulatory functions in complex conditions such as cancer and metabolic syndrome.